Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
about
Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell TransplantationGeneration of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.Recognition and management of platelet-refractory bleeding in patients with Glanzmann's thrombasthenia and other severe platelet function disordersComparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience.Platelet production from induced pluripotent stem cells.Platelet donor selection for HLA-immunised patients; the impact of donor-specific HLA antibody levels.Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation.How do I … manage the platelet transfusion-refractory patient?Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications.24-h continuous infusion of platelets for patients with platelet transfusion refractoriness.The Non-Hemostatic Aspects of Transfused Platelets.Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disordersA subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation
P2860
Q26767440-F9DAB7E8-E42C-4090-98B5-CE7D7969B420Q33432719-B72C3A9B-7160-4532-AE00-091A3FD26C31Q33437439-03AC453A-6DFF-4AD6-9AC3-9B6B9A617A9BQ33553506-8ABC8313-4FDB-4FDA-84B2-B167EA1AF266Q37265484-DC90A386-1D13-4073-94DE-BADF4BDF922BQ39149426-9F16BB68-82F5-4EBF-AA47-FFDB4BF0215FQ40115861-B3BBA8D2-1E03-4BC1-A296-277CE3669C84Q40262642-EDA032B9-8F70-4246-86A0-CB23B535F85CQ47156529-1307D925-C0EA-46B6-8D9E-2C4C27D89FBCQ47575948-616E7054-FCF5-40B0-A6DB-B74525B28245Q47667545-1E1F91AC-BB09-4F86-B07C-ADE2797145F6Q47913269-BF8A17F1-8DDA-4AC9-9AF2-7221899E8871Q48126340-C1A3849D-4AFB-4D58-86B7-91F3ADFDAB3EQ54941751-B373BC1F-ECA5-4D1F-A9C3-0CA80C843C7CQ55397497-D621EA87-C99E-4E47-BDA7-065F2A40BBF1Q57689300-2FD424B4-4DA0-4E77-85EA-02895903E582Q58793864-DE77B81B-1D0E-48DB-924C-0705280D541A
P2860
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
@en
type
label
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
@en
prefLabel
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
@en
P2093
P2860
P356
P1476
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management
@en
P2093
Cristina Navarrete
Judith Marsh
Simon J Stanworth
P2860
P304
P356
10.1111/BJH.13597
P407
P577
2015-07-20T00:00:00Z